Position in REPL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
3 quarters on record
Derivatives in REPL
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$2,295,000
PutShares
300,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Ikarian Capital, LLC holds $659,799,686 across 106 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
1,456,378 | $76,780,248 | |
| 2 | KOD |
Kodiak Sciences Inc.
|
1,265,795 | $48,252,105 | |
| 3 | ALMS |
Alumis Inc.
|
1,213,548 | $26,734,462 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
428,682 | $24,910,711 | |
| 5 | PRAX |
Praxis Precision Medicines, Inc.
|
71,581 | $23,062,682 | |
| 6 | RLMD |
Relmada Therapeutics, Inc.
|
2,688,359 | $18,710,978 | |
| 7 | CYTK |
Cytokinetics Inc
|
283,572 | $18,690,230 | |
| 8 | TENX |
Tenax Therapeutics, Inc.
|
1,017,600 | $16,271,424 |
All Filings in REPL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,295,000 | 300,000 | Put | Sole | 2026-05-15 | |
| 2023-09-30 | $39,780 | 2,325 | Call | Sole | 2023-11-14 | |
| 2023-09-30 | $93,044 | 5,438 | Put | Sole | 2023-11-14 | |
| 2023-06-30 | $8,085,204 | 348,200 | Put | Sole | 2023-08-14 | |
| 2023-06-30 | $5,301,126 | 228,300 | Call | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||